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Renal function is an indication of the state of the kidney and its role in renal physiology. Various conditions, diseases 
and drugs can affect the function of the kidneys. In 
clinical practice, plasma concentrations of the waste 
substances of creatinine and urea as well as electrolytes 
are used by physicians to determine renal function. 
Although these measures are adequate to determine 
whether a patient is suffering from kidney disease, 
blood urea nitrogen (BUN) and creatinine will not 
be raised above the normal range until 50% of total 
kidney function is lost.1 Hence, whenever renal disease 
is suspected or careful dosing of nephrotoxic drugs 
is required, the more accurate glomerular filtration 
rate (GFR), or its approximation by the creatinine 
clearance, is measured. The estimated glomerular 
filtration rate (eGFR) does not diagnose any kidney 
disease but is a test to assess how well your kidneys are 
working. During last few decades, various equations 
have evolved in an attempt to precisely measure GFR. 
Given SQUMJ articles on GFR in this and the previous 
issue, this editorial will discuss the latest advances 
made in GFR estimation.2–4
The level of GFR is accepted as the most useful 
index of kidney function in both healthy and 
diseased states. The determination of the GFR 
is a cumbersome procedure, ideally involving 
inulin infusion and urine collection under very 
standardised conditions. GFR is also estimated 
by measuring the clearance of other exogenous 
filtration markers such as iothalamate, iohexol and 
51chromium ethylene-diamine-tetra-acetic acid [51Cr] 
EDTA or technetium-99m-diethylenetriaminepentacetic 
acid [99mTc] DPTA. However, these methods are 
expensive and require exposure to radiation and 
compliance with strict regulatory guidelines, and thus 
have limited use in the routine laboratory settings. 
Besides, these tests are performed only when accurate 
information on kidney function is mandatory.
Serum creatinine (Cr), on the other hand, is 
freely filtered and has minimal tubular secretion 
and absorption. Its estimation from random blood 
samples is simple and inexpensive. It has relatively 
good accuracy and, for precisely these reasons, it has 
become a valuable clinical tool for estimating GFR. In 
clinical practice, a rise in serum Cr is used as a marker 
of reduced GFR, indicating it is inversely related with 
GFR. GFR can be estimated by measuring Cr clearance 
using serum Cr levels and a timed urine specimen.
There are, however, limitations on the use of 
serum Cr as an indirect filtration marker because of 
its biological variability, bias and non-specificity which 
affect Cr measurement, medication effects, nutrition 
and the alterations in circulating serum Cr produced 
by non-renal disease states.
Because of the differences in GFR range and Cr 
production between the two populations—healthy 
people versus patients with chronic kidney disease 
(CKD)—the estimation of GFR by serum Cr also 
differs between healthy people and patients with 
CKD. Hence, there is a risk of overestimating the GFR 
as a result of these confounding factors; in addition, 
we know that the magnitude of the overestimation 
is not predictable.5 This proportional variation in the 
GFR is larger in populations with the disease than in 
populations without it. As a result, a larger proportion 
of the variation in serum Cr levels among patients with 
the disease is due to a variation in the GFR, not to a 
variation in the other determinants as compared with 
healthy people. For example, among patients with the 
disease, a difference in levels of serum Cr of 0.8 and 
1.2 mg per decilitre (70.7 and 106.1 μmol per litre) 
probably reflects a difference in the GFR. In contrast, 
this same difference among healthy people more likely 
reflects a difference in muscle mass or protein intake 
rather than the GFR. When an estimating equation 
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derived in a population with CKD is applied to a 
healthy population, the equation will overstate the 
strength of the relationship of the GFR with the level 
of serum Cr. Thus, in people with an unusually low or 
high estimated GFR, the measured GFR would tend to 
fall closer to the normal GFR of the population than 
the GFR estimates.
Despite these limitations, plasma Cr is still 
measured as an estimate of the GFR in clinical practice, 
on the assumption that Cr is completely filtered across 
the glomerulus and that Cr production and excretion 
are constant. The limitations of Cr clearance and 
inulin clearance have inspired researchers to seek out 
easy formulas to estimate GFR.
The Cockcroft and Gault (C&G) formula is 
employed to measure Cr clearance, using plasma 
Cr concentration with a correction for age, sex and 
muscle mass.6 The C&G formula is effective only when 
plasma Cr is in a steady state; it is also inaccurate in 
cases of liver disease, oedema and muscle wasting or 
extreme adiposity.
It is important to remember that GFR estimation 
equations are mainly used for the systematic staging of 
CKD and should not be used in the setting of an acute 
rise in serum Cr. The modification of diet in renal 
disease (MDRD) GFR equation is mostly used for the 
estimation of GFR. It often out-performs the C&G 
equation in populations with a low range of GFR.3 
However, even this equation has several limitations, 
including age, disease state, and considerable variations 
in the standardisation of the serum Cr assays.
Plasma cystatin C (cys C) was proposed some 
years ago as an alternative endogenous substance 
for serum Cr in estimating the GFR because it has 
many properties of an ideal marker for GFR.7 Cys 
C is claimed to be a promising marker to monitor 
glomerular dysfunction, having a higher sensitivity 
and specificity than serum Cr and Cr clearance for 
small changes in GFR.4 Because of availability of 
immunonephelometric8 and immunoturbidimetric9 
methods, which allow a rapid and precise routine 
measurement, cys C has become a subject of great 
interest. A number of studies comparing cys C with 
plasma Cr have proved cystatin C is a more sensitive 
indicator of mild reductions of renal function than 
plasma Cr.10 However, despite considerable evidence, 
its role as an alternate marker for estimating GFR 
is still limited in clinical practice. There are several 
reasons for this, for example, a general diffidence 
among clinicians, the absence of definitive cut-off 
values, conflicting results in clinical studies, no clear 
evidence on when and how to request the test, the poor 
commutability of results and no accurate examination 
of costs and of its routine use.
Despite these facts, there are certain cases where 
Cr measurement is not appropriate; for example, cys 
C may be more reliable in cases with liver cirrhosis, 
beta thalassemia,4 morbid obesity and malnourished 
patients with a reduced muscle mass. This is true as 
we know that cys C is produced at a constant rate in 
all body cells, excreted by glomerular filtration and 
followed by catabolism in the tubular cells. Besides, it is 
also now known that there are non-GFR determinants 
of its serum level11,12 and there are studies suggesting 
that cys C is less dependent upon muscle mass than Cr, 
and therefore should provide more accurate estimate 
of GFR particularly in populations with differences in 
muscle mass.4,9–12
The more recent Cr-based formula, the Mayo 
Clinic Quadratic (MCQ) equation13 and the Chronic 
Kidney Disease Epidemiology Collaboration 
(CKD-EPI) equation proposed in 200914 improve 
underestimation, a well-recognised fact seen with 
the MDRD formula in patients with preserved kidney 
function, as both MCQ and CKD-EPI were derived 
from populations that included subjects with normal 
renal function.
The CKD-EPI equation was developed in a pooled 
dataset from 10 studies that included participants of 
diverse clinical characteristics, with and without kidney 
disease, and validated in a separate dataset pooled 
from 16 additional studies.13 The CKD-EPI equation 
was found to be more accurate than the MDRD Study 
equation, in the 16 studies used for its validation, with 
lower bias especially at an estimated GFR greater than 
60 ml/min per 1.73 m2; however, the precision was 
not substantially improved compared to the MDRD 
Study equation.14 Besides, there are weaknesses to this 
study, including relatively few participants older than 
70 years of age and racial minorities other than black, 
incomplete data on diabetes type, immunosuppressive 
agents for transplantation, measures of muscle mass 
and other clinical conditions and medications that 
might affect serum Cr independently from GFR. In 
addition, the CKD-EPI equation does not overcome 
the limitations of serum Cr as an endogenous filtration 
marker. Moreover, a comparison between MDRD 
and MCQ equations for GFR estimates provides 
significantly different results as the MCQ estimate 
provides suspiciously high GFR values. However, 
only direct comparison using the costly and complex 
clearance of an exogenous marker could unequivocally 
confirm the superiority of one method over the other.
Despite these limitations, serum Cr remains 
central at the present time for the evaluation of kidney 
function in clinical practice, and GFR estimates based 
on serum Cr will continue to be used in clinical 
practice for the foreseeable future.
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Further research is necessary to improve GFR 
estimation. Non-GFR determinants of Cr seem to 
be responsible for imprecision in GFR estimation. 
Measurement error in GFR also seems to contribute 
to this imprecision. Research, therefore, should be 
directed not only towards improving GFR measurement 
but evaluating the novel filtration markers for GFR 
estimation, either alone or in combination with serum 
Cr.15 Moreover, studies in representative populations, 
especially the elderly and racial and ethnic minorities, 
are also necessary.
In conclusion, significant advances have been made 
which have revolutionised our understanding of the 
performance and utilisation of GFR estimation in the 
current era. It is quite evident that a single equation will 
unlikely work equally well in all populations. However, 
given the current understanding, we believe, despite 
its limitations, that the new CKD-EPI equation, which 
uses the same four variables as the MDRD Study 
equation developed in people with and without kidney 
disease, has improved bias and risk prediction, without 
compromising the accuracy in people with CKD. It 
is an important step forward and should replace the 
MDRD Study equation for routine clinical use.
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